TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient report explains four leading theories about what drives Alzheimer’s disease: amyloid buildup, tau damage, inflammation and vascular dysfunction. The theories each account for part of the evidence, but the exact sequence and cause of neuronal loss remain unsettled.
Researchers have not established a single cause of Alzheimer’s disease, and a Being Patient report describes four leading theories for how the disease damages the brain: amyloid buildup, tau tangles, inflammation and vascular dysfunction. The explanations overlap and may describe connected parts of the disease process, but the report says each accounts for only part of what scientists observe.
Alzheimer’s progressively damages and kills neurons, disrupting the connections through which brain cells communicate. Damage often begins in the hippocampus, which plays a central role in forming new memories, and can later affect language, judgment, behavior and coordination. The disease’s characteristic brain changes include amyloid plaques between neurons and tau tangles inside them.
The amyloid hypothesis, which has guided much drug research for more than three decades, proposes that fragments of the beta-amyloid protein accumulate outside neurons and form plaques. Researchers think this buildup may start years before symptoms and may contribute to later damage, including tau changes. But the extent to which amyloid initiates the disease, rather than being one component of it, remains debated.
The tau theory focuses on a protein that helps maintain a neuron’s internal structure. When tau becomes abnormal and forms tangles, the cell’s internal transport system can be disrupted. The other two theories emphasize immune and inflammatory responses in the brain and problems involving blood vessels or blood flow. The supplied report identifies these as leading explanations, not settled, mutually exclusive causes.
Why the Cause Shapes Treatment
Theories about Alzheimer’s influence how researchers design treatments and tests. The amyloid explanation has led to drugs that target plaques, while tau, inflammation and vascular research explore other possible points of intervention. A better account of how these processes relate could help scientists identify which patients may benefit from which approaches and when treatment might work.
The report says two anti-amyloid antibodies, lecanemab (Leqembi) and donanemab (Kisunla), are FDA-approved for people in the early stages of Alzheimer’s. Clinical trials found that they modestly slowed cognitive decline; they do not cure the disease, and treatment carries risks including brain swelling and bleeding that require monitoring. The mixed history of amyloid-targeting drugs illustrates why biological evidence and clinical benefit are not the same thing.
The issue affects millions of families. The Alzheimer’s Association’s 2026 Facts and Figures report estimates that 7.4 million Americans age 65 and older are living with Alzheimer’s dementia. Understanding what remains uncertain helps readers distinguish established brain changes and available treatments from hypotheses about what starts the disease.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Theories
In 1906, German psychiatrist Alois Alzheimer described changes he observed in the brain of Auguste Deter, a former patient who died at 55 after years of worsening memory loss and confusion. The clumps and twisted fibers he reported are now known as amyloid plaques and tau tangles. They remain defining features of Alzheimer’s, but identifying them did not resolve why they form or which changes drive the disease.
Amyloid has also become part of Alzheimer’s testing. Plaques can be detected using amyloid PET scans and spinal-fluid tests, and the report says the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to the disease. Such tests can indicate a biological feature; they do not by themselves settle the wider question of what causes Alzheimer’s or predict an individual’s course.
The amyloid theory has produced both treatment advances and setbacks. Aduhelm (aducanumab) cleared plaques, but the source report says evidence of clinical benefit was unconvincing and its maker discontinued it in 2024. The newer antibody drugs have shown modest slowing of decline in trials, adding evidence that targeting amyloid can affect disease progression without establishing that amyloid alone explains the illness.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, as quoted by Being Patient
What Drives Neuron Loss
The initiating cause remains unknown. Researchers have not settled whether amyloid buildup starts a chain of events, whether tau or other processes play a more direct role in killing neurons, or how inflammation and vascular changes interact with these mechanisms. The theories may be connected rather than competing explanations, but the supplied report does not establish a definitive sequence.
It also remains unclear why some people develop Alzheimer’s while others do not, how strongly each process contributes in different patients, and whether changes seen in the brain are causes, consequences or both. Treatments that affect a biological marker do not automatically show that the marker is the disease’s sole cause. The report describes trial results and risks for specific drugs, but does not provide a full comparison of their benefits for individual patients.
These findings are scientific context, not personal medical guidance. Decisions about testing or treatment should be discussed with a qualified health professional, who can account for a person’s circumstances and the evidence available.
Evidence From Trials and Tests
The next evidence will come from continued clinical trials and research that compares biological markers with changes in cognition and daily function. Studies of amyloid-targeting drugs can clarify how much plaque removal affects progression, while research on tau, inflammation and vascular health may test whether targeting those processes changes outcomes. The source material does not identify a specific upcoming trial result or date.
For now, clinicians and researchers can use amyloid imaging, spinal-fluid testing and the blood test cleared in 2025 to help identify amyloid pathology, while treatment decisions remain distinct from the broader scientific question of causation. Further evidence is needed to show how the four theories fit together and which approaches are useful for which patients.
Key Questions
What are the four leading theories about Alzheimer’s?
The report discusses amyloid buildup, tau tangles, brain inflammation and vascular dysfunction. They are theories about mechanisms that may contribute to damage, not four proven, separate causes.
Has scientists’ amyloid theory been proven?
No single theory has been established as the complete cause. Amyloid is a defining feature and a major treatment target, but researchers continue to debate whether it initiates Alzheimer’s or is one part of a wider process.
Do current Alzheimer’s drugs cure the disease?
No. The source report says lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early stages. It also notes risks, including brain swelling and bleeding, and the need for regular monitoring.
Can a blood test determine what causes Alzheimer’s?
No. The report says the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s. Detecting amyloid does not establish the full cause of the disease or determine an individual’s future course.
Source: rss
